Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced a license agreement with Ablexis, LLC, a biopharmaceutical company focused on licensing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE